This was demonstrated by Coniglio et al. [65] in patients at risk of type 2 diabetes mellitus and those with metabolic syndrome, where high levels of non-HDL cholesterol predict higher CETP activity, which is also involved in decreasing HDL levels and antiatherogenic functions, possibly involving a gene mutation for this enzyme and associated with age [66]. Here, CETP is linked to metabolic syndrome.